Genmab Announces Final US Court Judgment in Favor of Arzerra in Patent Infringement Lawsuit

Genmab Announces Final US Court Judgment in Favor of Arzerra in Patent
Infringement Lawsuit

Company Announcement

  *Final ruling of U.S. Court of Appeals in favor of GSK in Arzerra patent
    infringement case

COPENHAGEN, Denmark, April 16, 2013 (GLOBE NEWSWIRE) -- Genmab A/S
(Copenhagen:GEN) announced today that the U.S. Court of Appeals for the
Federal Circuit has upheld the U.S. District Court's judgment in favor of
GlaxoSmithKline (GSK) in a patent infringement case involving Arzerra brought
against GSK by Genentech and Biogen Idec.

The two companies appealed the court order on the patent claim construction
which led to the judgment in favor of GSK in December 2011. The U.S. Court of
Appeals for the Federal Circuit has upheld the District Court's original
decision and the lawsuit is now over unless Genentech and Biogen Idec are
granted further review by the Federal Circuit or the Supreme Court.

Genentech and Biogen Idec originally filed the lawsuit in 2010 with the U.S.
District Court for the Southern District of California claiming Arzerra
infringed U.S. Patent No. 7,682,612 covering methods of treating Chronic
Lymphocytic Leukemia (CLL) with CD20 antibodies. GSK denied infringement and
claimed the patent was invalid and unenforceable.

Arzerra, Genmab's CD20 antibody, is partnered with GSK and is marketed in the
US and Europe as well as other territories.

About Genmab A/S

Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated human antibody therapeutics
for the treatment of cancer. Founded in 1999, the company's first marketed
antibody, ofatumumab (Arzerra(r)), was approved to treat chronic lymphocytic
leukemia in patients who are refractory to fludarabine and alemtuzumab after
less than eight years in development. Genmab's validated and next generation
antibody technologies are expected to provide a steady stream of future
product candidates. Partnering of innovative product candidates and
technologies is a key focus of Genmab's strategy and the company has alliances
with top tier pharmaceutical and biotechnology companies. For more
information visit

This Company Announcement contains forward looking statements. The words
"believe", "expect", "anticipate", "intend" and "plan" and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to
the outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment
in relation to our business area and markets, our inability to attract and
retain suitably qualified personnel, the unenforceability or lack of
protection of our patents and proprietary rights, our relationships with
affiliated entities, changes and developments in technology which may render
our products obsolete, and other factors. For a further discussion of these
risks, please refer to the risk management sections in Genmab's most recent
financial reports, which are available on . Genmab does not
undertake any obligation to update or revise forward looking statements in
this Company Announcement nor to confirm such statements in relation to actual
results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab(r); the
Y-shaped Genmab logo(r); the DuoBody(tm) logo; HuMax(r); HuMax-CD20(r);
DuoBody(r), HexaBody^TM and UniBody(r). Arzerra(r) is a trademark of

Company Announcement no. 13
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K

CONTACT: Rachel Curtis Gravesen, Senior Vice President,
         Investor Relations & Communications
         T: +45 33 44 77 20; M: +45 25 12 62 60
Press spacebar to pause and continue. Press esc to stop.